Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired PepGen Inc. securities between March 7, 2024 and March 3, 2025. PepGen is a ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

Eli Lilly and Company (NYSE:LLY) announced that the FDA has granted priority review to its new drug application (NDA) for ...

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their ...

The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gas­troin­testi­nal stro­mal tu­mour – a form of stomach cancer - after approving the drug in a narrower group ...